Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 11.94M P/E - EPS this Y - Ern Qtrly Grth -
Income -35.67M Forward P/E -0.11 EPS next Y -234.60% 50D Avg Chg 5.00%
Sales 10.19M PEG -0.04 EPS past 5Y - 200D Avg Chg -84.00%
Dividend N/A Price/Book 1.21 EPS next 5Y 40.00% 52W High Chg -97.00%
Recommedations 1.00 Quick Ratio 0.91 Shares Outstanding 9.24M 52W Low Chg 47.00%
Insider Own 11.64% ROA -34.53% Shares Float 8.14M Beta 0.83
Inst Own 1.14% ROE -290.94% Shares Shorted/Prior 370.66K/720.24K Price 0.62
Gross Margin 79.79% Profit Margin - Avg. Volume 2,464,404 Target Price 14.50
Oper. Margin -264.50% Earnings Date Nov 12 Volume 263,648 Change -1.93%
About Jaguar Health, Inc.

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Jaguar Health, Inc. News
11/22/24 Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
11/19/24 Jaguar Health Family Company Napo Therapeutics Named β€œBest Pharmaceuticals Innovator of the Year - Europe”
11/16/24 Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/14/24 Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
11/13/24 Jaguar Health Reports Third Quarter 2024 Financial Results
11/11/24 Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
11/06/24 FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
11/04/24 Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
10/29/24 Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
10/16/24 Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
10/11/24 Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/10/24 Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum
10/09/24 Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...
10/08/24 Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial
10/02/24 Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup
10/01/24 Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
09/26/24 Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors
09/25/24 Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
09/24/24 Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
09/16/24 Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference
JAGX Chatroom

User Image Rampart1 Posted - 5 hours ago

$JAGX keep in mind jagx is all natural. JFK JR is all about all natural. Prepare for a launch up. πŸš€

User Image Rampart1 Posted - 5 hours ago

$JAGX $CNSP $SBFM $ELAB in the past 4 years more than any algos and funders destroyed pennies with toxic offerings and a goal to short them to 0 if possible. Many are way oversold. Business susal will change soon and pennies will all run again.

User Image David_Shitchery Posted - 7 hours ago

$ELAB Based on this, I don't think a run is coming. https://www.streetinsider.com/Corporate+News/Elevai+Labs+%28ELAB%29+Files+for+28.37M+Share+and+Warrant+Offering/23724254.html As a matter of fact, I think this is just going to be like any other pipleine biotech like $JAGX, $SBFM, or $CNSP that gets immediatey shorted down again after the R/S. Everyone here has a shareholder bias that mames them think this company is more special than the any of the aforementioned, when it really isn't. I could be wrong. But oh wait...I can't remember the last time I was.

User Image Retail_Warrior Posted - 8 hours ago

$JAGX almost SABCS time, need to move up the sp so institutions will start buying.

User Image Tapemeasure Posted - 8 hours ago

$JAGX Almost got some of my money back today!

User Image Stock_Hunter65 Posted - 10 hours ago

$JAGX πŸ‘€

User Image Shoaquannic Posted - 10 hours ago

$JAGX

User Image YFZ450 Posted - 11 hours ago

$JAGX easy block lol proof the truth hurts.... sad sad sad

User Image Rampart1 Posted - 11 hours ago

$JAGX easy block. Paid hedge fund trolls.

User Image YFZ450 Posted - 12 hours ago

$JAGX people probably follow this guy and will take their accounts to the grave with him lol no wonder the market is so manipulated... its like taking candy from a baby with retail...

User Image Torobravo_1 Posted - 12 hours ago

$JAGX Are there still bears here? πŸ€¦β€β™‚οΈ

User Image YFZ450 Posted - 12 hours ago

$JAGX if after this next RS you don't jump in short with everything you have you honestly don't deserve to be handling your own money... ignorance is not bliss in the market... Bulls down 99% and will continue the same path... imagine if you pulled your head out and bet the other way...

User Image ScottyDoesntKnowMeSon Posted - 13 hours ago

$JAGX $16 No partner needed

User Image darfichdichmal Posted - 14 hours ago

$JAGX https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-seeking-partner-develop-and-commercialize-np300

User Image darfichdichmal Posted - 14 hours ago

$JAGX https://www.tipranks.com/news/the-fly/jaguar-health-seeking-partner-to-develop-commercialize-np300

User Image Torobravo_1 Posted - 14 hours ago

$JAGX It is a speculative stock, but at the same time with many catalysts, attractive products, which is easy if Lisa lets it run float 7.71M

User Image Rampart1 Posted - 14 hours ago

$JAGX like wow man. πŸ€™πŸ»

User Image byers07 Posted - 14 hours ago

$JAGX Looks to me like it is coming out of a base pattern. Curling up next week IMO

User Image Awaywegomoon Posted - 14 hours ago

$JAGX nobody wants to be a partner to a product that dosent make more than my little sister that works at mcdonalds.

User Image Awaywegomoon Posted - 15 hours ago

$JAGX lol, hanible brought up the same point i did. Revenues for canalevia for dogs is minimal at best. They talk about exersise induced diarrhea in dogs but what responsible dog owner overworks their dog? Certainly not one that cares if it gets diarrhea. A responsible dog owner gets a remedy that works the same day, not weeks.

User Image Torobravo_1 Posted - 16 hours ago

$JAGX Soon this will cost more than 6 dollars

User Image Torobravo_1 Posted - 16 hours ago

$JAGX Pivot Point 3rd Level Resistance 1.0420

User Image Torobravo_1 Posted - 16 hours ago

$JAGX he who seeks, finds... buy and stay long

User Image Rampart1 Posted - 16 hours ago

$JAGX these PRs are great. Can't wait until hedge funds and MMs release these to run. πŸ’ͺ🏻πŸ’ͺ🏻

User Image Awaywegomoon Posted - 17 hours ago

$JAGX The absolute most absurd p.R. In history. Sb 300 is crofelemer! Just cheaper to make supposedly. Why would you need to use sb300 when you only sell $45k worth per quarter for dogs??.

User Image Hannibal_Smith Posted - 17 hours ago

$JAGX I mean by this... As a company... keep the focus on the data readout of CID in breast cancer patients. SABCS will release the abstract text monday november 25th after market close. PR problably pre market tuesday. Keep the focus on that instead of this non PR

User Image TimeForChangeNow Posted - 17 hours ago

$JAGX Thats the news, that will not make any monies here WTH. CRAP!

User Image Hannibal_Smith Posted - 17 hours ago

$JAGX Let's be honest... These PR's are useless, and secondly.. We have seen what Canalevia generates as revenue... it's not particularly what this stock needs

User Image RazorETC_F150Lightning Posted - 17 hours ago

$JAGX conversations with the new partner could already be happening πŸ™πŸ½πŸ€žπŸ½πŸ€·πŸ½β€β™‚οΈ

User Image DonCorleone77 Posted - 17 hours ago

$JAGX Jaguar Health seeking partner to develop, commercialize NP300 Jaguar Health announced that it is seeking a partner to fund and execute the development and commercialization of NP300, the company's prescription drug candidate for the treatment of general, non-infectious diarrhea in dogs, in exchange for commercial rights to the product in the U.S. NP300 is a novel antisecretory drug with a similar mechanism of action to Canalevia-CA1, the company's conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs. NP300 has demonstrated safety in dogs and is sustainably derived from the Croton lechleri tree, the same source as that for crofelemer.

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Wolin Jonathan S. Chief of Staff, CCO.. Chief of Staff, CCO & GC Dec 31 Buy 0.03 317 10 6,983 01/03/23
Lizak Carol R. Chief Financial Offi.. Chief Financial Officer Sep 13 Buy 2.51 7,968 20,000 7,968 03/30/22
CONTE LISA A CEO and President CEO and President Sep 13 Buy 2.51 7,968 20,000 8,003 03/30/22